Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
42nd Annual CFS: Chemotherapy Foundation Symposium®: Innovative Cancer Therapy for Tomorrow
View More
Updated Results for Nivolumab in MSI-H Colorectal Cancer
March 7th 2017Michael J. Overman, MD, medical oncologist, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses updated results from the CheckMate-142 trial, which investigated nivolumab alone or in combination with ipilimumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer.
Watch
Welling to Lead New Liver Cancer Program at NYU Langone
February 20th 2017NYU Langone has announced Theodore H. Welling III, MD, will lead a new state-of-the-art liver cancer program at the medical center to advance clinical care and accelerate the translation of lab breakthroughs into superior treatments.
Read More
Four-Drug CRC Regimen Demonstrates Modest PFS Gain
February 14th 2017The results of a randomized trial showed patients with advanced colorectal cancer had a modest gain in progression-free survival with the addition of irinotecan to standard chemotherapy plus an angiogenesis inhibitor as induction therapy.
Read More
Expert Speaks on PD-1 Success in Second-Line MSI-H Colorectal Cancer
February 10th 2017The latest clinical trial data strongly support anti–PD-1 therapy as the new second-line treatment standard for patients with microsatellite instability-high metastatic colorectal cancer, says Michael J. Overman, MD.<br />
Read More
Arginine-Depleting Agent Added to Standard Therapy Shows Promise in Pancreatic Cancer
February 9th 2017The addition of ADI-PEG 20, a pegylated form of an arginine-depleting enzyme, to nab-paclitaxel and gemcitabine has encouraging activity in patients with advanced pancreatic adenocarcinoma while demonstrating minimal additional toxicity over that with cytotoxic therapy alone.
Read More
MPC Treatment Costs Lower with Nab-Paclitaxel/Gemcitabine Than FOLFIRINOX
February 8th 2017<span style="font-size:12px">Treatment administration and supportive care costs were significantly higher for patients with metastatic pancreatic cancer who were treated with FOLFIRINOX as first-line therapy compared with the combination of nab-paclitaxel and gemcitabine.</span>
Read More
Nanoliposomal Irinotecan Regimen Improves OS in Pancreatic Cancer
February 8th 2017Overall survival was improved and disease progression was slowed in patients with metastatic pancreatic ductal adenocarcinoma when nanoliposomal irinotecan was added to 5-fluorouracil and leucovorin, irrespective of treatment history, a posthoc analysis of a randomized trial showed.
Read More
Atezolizumab/Bevacizumab Combo Well Tolerated in MSI-High mCRC
February 8th 2017An immunotherapy-containing regimen was well-tolerated and had a manageable safety profile in patients with microsatellite-high metastatic colorectal cancer, according to results of a preliminary clinical evaluation presented at the 2017 Gastrointestinal Cancers Symposium<span style="font-size:10.8333px">.</span>
Read More
Study Findings Show Highly Effective Colorectal Cancer Treatment is Underutilized
February 2nd 2017Patients receiving the same diagnosis, colorectal cancer with synchronous peritoneal metastases (PM), were offered different treatments that led to dramatically different outcomes based upon the institution in which they were diagnosed.
Read More
Learning From Negative Clinical Trials in Pancreatic Cancer
January 26th 2017Philip A. Philip, MD, PhD, professor of oncology and pharmacology, Karmanos Cancer Institute, Wayne State University, discusses how researchers in the pancreatic cancer field can learn from recent negative clinical trials.
Watch
CCR2 Blockade Holds Clinical Promise in Advanced or Metastatic Pancreatic Cancer
January 25th 2017CCX872-B, a potent, selective oral inhibitor of CCR2, added to FOLFIRINOX was associated with a tumor control rate of 78% at week 12 in a single-arm study of patients with locally advanced or metastatic pancreatic cancer.
Read More
Chemotherapy/Immunotherapy Regimen Active in Treated, Untreated Pancreatic Cancer
January 25th 2017Encouraging clinical activity with limited toxicity in patients with metastatic pancreatic cancer will lead to further evaluation of nivolumab plus nab-paclitaxel with gemcitabine, investigators reported at the Gastrointestinal Cancers Symposium in San Francisco.
Read More
Vemurafenib Prolongs PFS in BRAF-Mutant mCRC
January 25th 2017According to results from a randomized clinical trial,<sup> </sup>adding vemurafenib to the routinely employed combination of irinotecan and cetuximab prolonged progression-free survival in patients with <em>BRAF</em>-mutant metastatic colorectal cancer.
Read More
Tarextumab in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
January 23rd 2017Eileen M. O’Reilly, MD, discusses results of a randomized phase II trial of tarextumab in combination with nab-paclitaxel and gemcitabine in patients with untreated metastatic pancreatic cancer.
Watch